S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.31 (-0.83%)
MSFT   313.12 (-2.70%)
META   300.66 (-2.01%)
GOOGL   132.38 (-1.33%)
AMZN   124.73 (-3.65%)
TSLA   246.48 (-2.03%)
NVDA   434.99 (-2.86%)
NIO   8.63 (-1.82%)
BABA   84.62 (-2.21%)
AMD   100.06 (-3.11%)
T   14.78 (+0.75%)
F   12.09 (-1.79%)
MU   67.77 (-0.28%)
CGC   0.70 (-5.60%)
GE   107.55 (-1.14%)
DIS   79.57 (-2.57%)
AMC   7.89 (-3.19%)
PFE   33.91 (-0.09%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.31 (-0.83%)
MSFT   313.12 (-2.70%)
META   300.66 (-2.01%)
GOOGL   132.38 (-1.33%)
AMZN   124.73 (-3.65%)
TSLA   246.48 (-2.03%)
NVDA   434.99 (-2.86%)
NIO   8.63 (-1.82%)
BABA   84.62 (-2.21%)
AMD   100.06 (-3.11%)
T   14.78 (+0.75%)
F   12.09 (-1.79%)
MU   67.77 (-0.28%)
CGC   0.70 (-5.60%)
GE   107.55 (-1.14%)
DIS   79.57 (-2.57%)
AMC   7.89 (-3.19%)
PFE   33.91 (-0.09%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.31 (-0.83%)
MSFT   313.12 (-2.70%)
META   300.66 (-2.01%)
GOOGL   132.38 (-1.33%)
AMZN   124.73 (-3.65%)
TSLA   246.48 (-2.03%)
NVDA   434.99 (-2.86%)
NIO   8.63 (-1.82%)
BABA   84.62 (-2.21%)
AMD   100.06 (-3.11%)
T   14.78 (+0.75%)
F   12.09 (-1.79%)
MU   67.77 (-0.28%)
CGC   0.70 (-5.60%)
GE   107.55 (-1.14%)
DIS   79.57 (-2.57%)
AMC   7.89 (-3.19%)
PFE   33.91 (-0.09%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
S&P 500   4,229.45 (-1.37%)
DOW   33,002.38 (-1.29%)
QQQ   354.62 (-1.84%)
AAPL   172.31 (-0.83%)
MSFT   313.12 (-2.70%)
META   300.66 (-2.01%)
GOOGL   132.38 (-1.33%)
AMZN   124.73 (-3.65%)
TSLA   246.48 (-2.03%)
NVDA   434.99 (-2.86%)
NIO   8.63 (-1.82%)
BABA   84.62 (-2.21%)
AMD   100.06 (-3.11%)
T   14.78 (+0.75%)
F   12.09 (-1.79%)
MU   67.77 (-0.28%)
CGC   0.70 (-5.60%)
GE   107.55 (-1.14%)
DIS   79.57 (-2.57%)
AMC   7.89 (-3.19%)
PFE   33.91 (-0.09%)
PYPL   57.30 (-2.15%)
NFLX   376.75 (-0.94%)
NASDAQ:CMPX

Compass Therapeutics (CMPX) Competitors

$1.91
-0.02 (-1.04%)
(As of 04:00 PM ET)
Compare
Today's Range
$1.87
▼
$1.93
50-Day Range
$1.87
▼
$2.87
52-Week Range
$1.83
▼
$5.65
Volume
129,551 shs
Average Volume
410,358 shs
Market Capitalization
$243.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.05
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

CMPX vs. ALVR, ABOS, SCLX, ALVO, ZURA, VIGL, HUMA, PSTX, IPHA, and MESO

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include AlloVir (ALVR), Acumen Pharmaceuticals (ABOS), Scilex (SCLX), Alvotech (ALVO), Zura Bio (ZURA), Vigil Neuroscience (VIGL), Humacyte (HUMA), Poseida Therapeutics (PSTX), Innate Pharma (IPHA), and Mesoblast (MESO). These companies are all part of the "biological products, except diagnostic" industry.

Compass Therapeutics vs.

Compass Therapeutics (NASDAQ:CMPX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.

AlloVir received 7 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 68.97% of users gave Compass Therapeutics an outperform vote while only 64.29% of users gave AlloVir an outperform vote.

CompanyUnderperformOutperform
Compass TherapeuticsOutperform Votes
20
68.97%
Underperform Votes
9
31.03%
AlloVirOutperform Votes
27
64.29%
Underperform Votes
15
35.71%

Compass Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass TherapeuticsN/AN/A-$39.22M-$0.37-5.16
AlloVirN/AN/A-$168.71M-$1.79-1.15

Compass Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

In the previous week, Compass Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Compass Therapeutics and 2 mentions for AlloVir. Compass Therapeutics' average media sentiment score of 0.64 beat AlloVir's score of 0.29 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Compass Therapeutics Positive
AlloVir Neutral

71.0% of Compass Therapeutics shares are held by institutional investors. Comparatively, 47.4% of AlloVir shares are held by institutional investors. 30.0% of Compass Therapeutics shares are held by insiders. Comparatively, 40.0% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Compass Therapeutics' return on equity of -26.62% beat AlloVir's return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -26.62% -24.58%
AlloVir N/A -74.04%-60.74%

Compass Therapeutics presently has a consensus target price of $9.05, indicating a potential upside of 376.32%. AlloVir has a consensus target price of $18.75, indicating a potential upside of 814.63%. Given AlloVir's higher probable upside, analysts clearly believe AlloVir is more favorable than Compass Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
AlloVir
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Compass Therapeutics beats AlloVir on 10 of the 14 factors compared between the two stocks.


Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

Export to Excel
MetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$243.45M$2.66B$4.42B$6.20B
Dividend YieldN/A2.27%5.86%7.83%
P/E Ratio-5.164.79121.3111.96
Price / SalesN/A156.222,883.2766.39
Price / CashN/A25.9721.3922.77
Price / Book1.333.323.824.56
Net Income-$39.22M$63.19M$121.29M$181.66M
7 Day Performance-4.02%-4.60%-2.00%-1.97%
1 Month Performance-19.75%-11.85%-7.91%-9.14%
1 Year Performance-25.10%13.20%7.16%1.95%

Compass Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVR
AlloVir
2.1414 of 5 stars		$2.27
-3.4%		$18.75
+726.0%		-74.8%$258.49MN/A-1.27113Short Interest ↑
Gap Down
High Trading Volume
ABOS
Acumen Pharmaceuticals
2.2173 of 5 stars		$4.29
+1.2%		$15.75
+267.1%		-58.4%$248.26M$1.44M-3.7639News Coverage
Positive News
SCLX
Scilex
0 of 5 stars		$1.56
-4.9%		N/AN/A$232.53M$46.46M0.00100Positive News
Gap Up
ALVO
Alvotech
0 of 5 stars		$8.93
flat		$9.00
+0.8%		+33.4%$279.06M$63.17M0.00917News Coverage
Positive News
ZURA
Zura Bio
2.1261 of 5 stars		$6.60
-3.4%		$18.25
+176.5%		N/A$284.39MN/A0.00N/A
VIGL
Vigil Neuroscience
1.9712 of 5 stars		$6.07
+1.3%		$18.40
+203.1%		-45.4%$217.75MN/A-2.9861Positive News
HUMA
Humacyte
1.7892 of 5 stars		$2.84
-0.7%		$8.10
+185.2%		-13.5%$293.74M$1.57M-3.26164Gap Down
PSTX
Poseida Therapeutics
2.4056 of 5 stars		$2.38
+13.9%		$14.33
+503.5%		-35.1%$206.44M$130.49M-9.90348
IPHA
Innate Pharma
2.0486 of 5 stars		$2.49
-6.0%		$9.63
+286.5%		+29.5%$200.32M$60.78M0.00211High Trading Volume
MESO
Mesoblast
2.4046 of 5 stars		$1.23
+0.8%		$7.13
+479.3%		-53.2%$200.29M$7.50M-2.2083Short Interest ↓
Gap Down

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:CMPX) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -